Clinical and virological outcome in patients with advanced hiv starting integrase inhibitors- based regimen : (Record no. 178627)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 06045namaa22004571i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | EG-GICUC |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20260303104009.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 260221s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.97920072 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 616.97920072 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.11.33.Ph.D.2025.Ay.C |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Aya Mohamed Hassan Ahmed, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Clinical and virological outcome in patients with advanced hiv starting integrase inhibitors- based regimen : |
| Remainder of title | A prospective cohort study / |
| Statement of responsibility, etc. | by Aya Mohamed Hassan Ahmed ; Supervised Prof. Dr. Rasha Ahmed Abdalaziz, Prof. Dr. Zeinab Abdellatif Mahmoud Soliman, Prof. Dr. Mohamed Mohamed Bassam Hashem, Prof. Dr. Hend Hamed Tamim. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | النتائج السريرية والفيروسية في المرضى الذين يعانون من فيروس نقص المناعة البشرية المتقدم على نظام قائم على مثبطات الإنزيم : |
| Remainder of title | دراسة جماعية مستقبلية |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2025. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 97 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (Ph.D)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 72 -97. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | Background: Advanced HIV disease (AHD) affects approximately 30% of <br/>people with HIV who present with severe immunosuppression. Limited data <br/>exists on optimal integrase inhibitor-based treatment for AHD patients, <br/>particularly in the Middle East and North Africa region. <br/>Objective: To evaluate clinical, immunological, and virological responses to <br/>integrase-based antiretroviral therapy (ART) over nine months in treatment-naïve <br/>AHD patients and identify early mortality predictors. <br/>Methods: This prospective cohort study at Cairo University's HIV Clinic (March <br/>2023-August 2024) enrolled 51 treatment-naïve patients with AHD (CD4 <200 <br/>cells/mm³ or AIDS-defining illnesses). Comprehensive assessments included <br/>clinical evaluation, laboratory parameters, imaging studies, and nutritional status <br/>using composite malnutrition scores. <br/>Results: Participants averaged 37.6 years (76% male) with baseline median CD4 <br/>count of 80 cells/mm³ and HIV RNA of 91,800 copies/mL. Malnutrition and <br/>opportunistic infections each affected 23.5% of patients. Survivors demonstrated <br/>significant improvements: weight increased from 64.61 to 71.11 kg, CD4 count <br/>rose from 92.57 to 235.76 cells/mm³, and 100% achieved viral suppression by <br/>month nine. However, early mortality was critically high at 23.5%, with 75% of <br/>deaths occurring within three months. Mortality predictors included severe <br/>malnutrition, lower mid-upper arm circumference and BMI, hypoalbuminemia, <br/>CD4 <50 cells/mm³, viral load >100,000 copies/mL, and multiple organ <br/>abnormalities. <br/>Conclusion: While integrase inhibitor-based ART produces excellent responses <br/>in AHD survivors, early mortality remains dangerously high. Poor nutritional <br/>status, severe immunosuppression, and multi-organ involvement strongly predict <br/>mortality, emphasizing the need for earlier HIV diagnosis and comprehensive <br/>nutritional support in resource-limited settings. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | يظل المرض المتقدم لفيروس نقص المناعة البشرية تحدياً صحياً رئيسياً، نظراً لارتفاع معدلات الاعتلال والوفيات المرتبطة به، حتى في عصر العلاج المضاد للفيروسات (ART). قامت هذه الدراسة الجماعية في جامعة القاهرة بتسجيل 51 بالغاً غير خاضعين للعلاج سابقاً، ممن يعانون من نقص المناعة المكتسب المتقدم وبدأوا أنظمة علاج تعتمد على مثبطات الإنزيم المدمج. أظهر المشاركون في بداية الدراسة ضعفاً شديداً في المناعة وسوء تغذية، لكن العلاج أدى إلى تحسن ملحوظ في عدد خلايا الدم البيضاء اللمفاويةCD4، والعلامات التغذوية، وقوة العضلات خلال 9 أشهر. وعلى الرغم من النجاح الفيروسي والالتزام العالي بالعلاج بين الناجين، كانت الوفيات المبكرة كبيرة، خاصة خلال أول 3 أشهر. شملت مؤشرات الوفاة عدد CD4 المنخفض، الحمل الفيروسي المرتفع، نقص الألبومين، فقر الدم، سوء المؤشرات الجسمانية، ارتفاع إنزيمات الكبد، وتاريخ نقل الدم. وتؤكد هذه النتائج أهمية التقييم الغذائي والمناعي المبكر لتوجيه التدخلات المصممة خصيصاً وتقليل معدلات الوفيات في هذه الفئة عالية الخطورة |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | HIV |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | فيروس نقص المناعة البشرية |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Advanced HIV Disease (AHD) |
| -- | Early Mortality |
| -- | Integrase Inhibitors |
| -- | Nutritional Assessment |
| -- | المرض المتقدم لفيروس نقص المناعة البشرية |
| -- | مثبطات الإنزيم المدمج |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rasha Ahmed Abdalaziz |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Zeinab Abdellatif Mahmoud Soliman |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mohamed Mohamed Bassam Hashem |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hend Hamed Tamim |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2025 |
| Supervisory body | Rasha Ahmed Abdalaziz |
| -- | Zeinab Abdellatif Mahmoud Soliman |
| -- | Mohamed Mohamed Bassam Hashem |
| -- | Hend Hamed Tamim |
| Universities | Cairo University |
| Faculties | Faculty of Medicine |
| Department | Department of Infectious Diseases and Endemic Hepatogastroenterology |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 21.02.2026 | 93434 | Cai01.11.33.Ph.D.2025.Ay.C | 01010110093434000 | 21.02.2026 | 21.02.2026 | Thesis |